Company / Operating Cash Flow per Share
Neogen Operating Cash Flow per Share History
FY2016-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow per Share
$0.27
FY2024
5-year range
$0.27 / $0.64
FY2020-FY2024
Trend
-17.7%
vs FY2023
Sector context
#126 of 155
Health Care
What the data says
Neogen's operating cash flow per share of $0.27 is lower than 81% of companies in the Health Care sector (FY2024). Operating Cash Flow per Share has declined for 5 consecutive years, from $1.66 in FY2019 to $0.27 in FY2024.
Based on SEC 10-K filings.
0.27 in FY2024 with a 5-year CAGR of -30.5%.
Declined from $0.38 to $0.27 over the past 2 years.
Health Care sector context is included.
Operating Cash Flow per Share over time
Growth rates
- 3-Year CAGR
- -25.2%
- 5-Year CAGR
- -30.5%
- 10-Year CAGR
- -
Sector benchmark
Bottom 19% in Health CareTop 81% of 155This company $0.27 Sector average $6.77
▼
-96.0% below sector average
Key checks
Key Insights
- Neogen's operating cash flow per share has declined for 5 consecutive years.
- In FY2024, operating cash flow per share decreased 17.7% year-over-year.
- Ranks #126 out of 155 companies in the Health Care sector.
- Peak operating cash flow per share was recorded in FY2017.
Company context
Key Data Points
- Low Piotroski F-Score: 0/9 (multiple financial health concerns)
- Altman Z-Score 0.59 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash Flow per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | $0.27 | -17.7% |
| FY2023 | $0.33 | -14.3% |
| FY2022 | $0.38 | -40.6% |
| FY2021 | $0.64 | -58.6% |
| FY2020 | $1.55 | -6.4% |
| FY2019 | $1.66 | +32.4% |
| FY2018 | $1.25 | -31.9% |
| FY2017 | $1.84 | +13.4% |
| FY2016 | $1.62 | +68.8% |
As of FY2024 · SEC 10-K · Updated Mar 28, 2026